Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter F. Wadsworth is active.

Publication


Featured researches published by Peter F. Wadsworth.


Cancer Research | 2005

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge; Jane Kendrew; Laurent Francois Andre Hennequin; Paula J. Valentine; Simon T. Barry; Sandra R. Brave; Neil R. Smith; Neil H. James; Michael Dukes; Jon Owen Curwen; Rosemary Chester; Janet A. Jackson; Sarah J. Boffey; Lyndsey L. Kilburn; Sharon Barnett; Graham Richmond; Peter F. Wadsworth; Michael D. Walker; Alison L. Bigley; Sian Tomiko Taylor; Lee A. D. Cooper; Sarah Beck; Juliane M. Jürgensmeier; Donald J. Ogilvie

Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a promising therapeutic approach that aims to stabilize the progression of solid malignancies by abrogating tumor-induced angiogenesis. This may be accomplished by inhibiting the kinase activity of VEGF receptor-2 (KDR), which has a key role in mediating VEGF-induced responses. The novel indole-ether quinazoline AZD2171 is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. Concordant with this activity, in human umbilical vein endothelial cells, AZD2171 inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 and 0.5 nmol/L, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, AZD2171 also reduced vessel area, length, and branching at subnanomolar concentrations. Once-daily oral administration of AZD2171 ablated experimental (VEGF-induced) angiogenesis in vivo and inhibited endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice was inhibited dose-dependently by AZD2171, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with AZD2171 revealed a reduction in microvessel density within 52 hours that became progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors. Collectively, the data obtained with AZD2171 are consistent with potent inhibition of VEGF signaling, angiogenesis, neovascular survival, and tumor growth. AZD2171 is being developed clinically as a once-daily oral therapy for the treatment of cancer.


Laboratory Animals | 1981

Organ weight data in juvenile and adult marmosets (Callithrix jacchus)

Peter F. Wadsworth; David A. Budgett; Margaret L. Forster

Organ weight data from 167 (82 male and 85 female) juvenile and adult common cotton-eared marmosets (Callithrix jacchus) is presented. The marmosets were bred in captivity and were used as untreated or vehicle control animals in safety evaluation studies carried out over an 8 year period.


Laboratory Animals | 1978

Segmental aplasia of the vagina in the beagle bitch

Peter F. Wadsworth; Janet C. Hall; David E. Prentice

Segmental aplasia of the vaginal mucosa was discovered in 3 beagle bitches at the end of a routine toxicological experiment. Anomalies of Müllerian duct development in the bitch are discussed.


Laboratory Animals | 1982

Haematological, coagulation and blood chemistry data in red-bellied tamarins Saguinus labiatus

Peter F. Wadsworth; William A. Hiddleston; David V. Jones; John S. L. Fowler; Robert A. Ferguson

Haematology, coagulation and clinical chemistry data are reported for a group of male and female red-bellied tamarins (Saguinus labiatus). The tamarins were juvenile and young adults and were bred in captivity. High mean values for activities of alkaline phosphatase, alanine amino-transferase, aspartate aminotransferase and creatine kinase were noted. The findings are compared with data obtained from other members of the family Callitrichidae.


Laboratory Animals | 1992

A case of endometriosis in the macaque diagnosed by nuclear magnetic resonance imaging

John C. Waterton; Diane Miller; John S. W. Morrell; Michael Dukes; Christoper D. West; Peter F. Wadsworth

A case of spontaneous endometriosis was diagnosed in the pigtailed macaque (Macaca nemestrina nemestrina) with the aid of high-field (2·35 T), T2-weighted (TE50), C1H2-suppressed, oblique nuclear magnetic resonance imaging (MRI). Postmortem histology was obtained. A variety of endometriotic lesions was seen with MRI, including extrauterine hyperintense apparently cystic regions, extrauterine hypointense regions apparently associated with intracellular paramagnetic iron proteins, and an enlarged myometrium exhibiting adenomyosis foci.


Laboratory Animals | 1980

Renal aplasia and hypoplasia in the rhesus monkey (Macaca mulatta)

Peter F. Wadsworth; Peter F. Squires

Unilateral renal aplasia or hypoplasia was discovered in 3 wild-caught rhesus monkeys at the end of routine toxicological experiments. No clinical abnormalities were evident and the opposite kidneys had undergone compensatory hypertrophy and hyperplasia.


Cancer Research | 2002

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge; Donald J. Ogilvie; Michael Dukes; Jane Kendrew; Rosemary Chester; Janet A. Jackson; Sarah J. Boffey; Paula J. Valentine; Jon Owen Curwen; Helen Musgrove; George A. Graham; Gareth Hughes; Andrew Peter Thomas; Elaine Sophie Elizabeth Stokes; Brenda Curry; Graham Richmond; Peter F. Wadsworth; Alison L. Bigley; Laurent Francois Andre Hennequin


Cancer Research | 2000

ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy

Stephen R. Wedge; Donald J. Ogilvie; Michael Dukes; Jane Kendrew; Jon Owen Curwen; Laurent Francois Andre Hennequin; Andrew Peter Thomas; Elaine Sophie Elizabeth Stokes; Brenda Curry; Graham Richmond; Peter F. Wadsworth


Experimental and Toxicologic Pathology | 2003

Revised guides for organ sampling and trimming in rats and mice - Part 1 A joint publication of the RITA*) and NACAD**) groups

Birgit Kittel; Christine Ruehl-Fehlert; Gerd Morawietz; Jan Klapwijk; Michael R. Elwell; Barbara Lenz; M. Gerard O'Sullivan; Daniel Robert Roth; Peter F. Wadsworth


Anticancer Research | 2003

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

Seiichi Yano; Kaoru Kondo; Motonori Yamaguchi; Graham Richmond; Michael Hutchison; Alan E. Wakeling; Steven D. Averbuch; Peter F. Wadsworth

Collaboration


Dive into the Peter F. Wadsworth's collaboration.

Researchain Logo
Decentralizing Knowledge